Academic Journal
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
| العنوان: | Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer |
|---|---|
| المؤلفون: | Guerini-Rocco E., Venetis K., Cursano G., Mane E., Frascarelli C., Pepe F., Negrelli M., Olmeda E., Vacirca D., Ranghiero A., Trapani D., Criscitiello C., Curigliano G., Rolfo C., Malapelle U., Fusco N. |
| المساهمون: | E. Guerini-Rocco, K. Veneti, G. Cursano, E. Mane, C. Frascarelli, F. Pepe, M. Negrelli, E. Olmeda, D. Vacirca, A. Ranghiero, D. Trapani, C. Criscitiello, G. Curigliano, C. Rolfo, U. Malapelle, N. Fusco |
| بيانات النشر: | Elsevier Ireland Ltd |
| سنة النشر: | 2024 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | CtDNA, Digital PCR, ESR1 testing, Metastatic breast cancer, Next-generation sequencing, Pathology report, Settore MED/08 - Anatomia Patologica |
| الوصف: | Mutations in the estrogen receptor alpha gene (ESR1) can lead to resistance to endocrine therapy (ET) in hormone receptor-positive (HR+)/ HER2- metastatic breast cancer (MBC). ESR1 mutations can be detected in up to 40 % of patients pretreated with ET in circulating tumor DNA (ctDNA). Data from prospective randomized trials highlight those patients with HR+/HER2- MBC with detectable ESR1 mutations experience better outcomes when receiving novel selective estrogen receptor degraders (SERDs). There is a high need for optimizing ESR1 testing strategies on liquid biopsy samples in HR+/HER2- MBC, including a hugh quality workflow implementation and molecular pathology reporting standardization. Our manuscript aims to elucidate the clinical and biological rationale for ESR1 testing in MBC, while critically examining the currently available guidelines and recommendations for this specific type of molecular testing on ctDNA. The objective will extend to the critical aspects of harmonization and standardization, specifically focusing on the pathology laboratory workflow. Finally, we propose a clear and comprehensive model for reporting ESR1 testing results on ctDNA in HR+/HER2- MBC. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:001260626200001; volume:201; firstpage:1; lastpage:6; numberofpages:6; journal:CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; https://hdl.handle.net/2434/1087409; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85196819808 |
| DOI: | 10.1016/j.critrevonc.2024.104427 |
| الاتاحة: | https://hdl.handle.net/2434/1087409 https://doi.org/10.1016/j.critrevonc.2024.104427 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.D8783827 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.critrevonc.2024.104427 |
|---|